Did you miss "Mad Money" on CNBC? If so, here are some of Jim Cramer's top takeaways.
For an "Executive Decision" segment, Cramer spoke with Randall Schatzman, co-founder, president and CEO of Alder BioPharmaceuticals (ALDR) , a stock that shot up 40% this week on the heels of positive clinical trial results.
Schatzman explained that the results that were just released were Phase III results for chronic migraine suffers. On average, these patients had 16 episodes a month. With Eptinezumab, migraines decreased by 50% on day one of the trial and 15% of patients reporting zero incidents for the entire 12 weeks of the trial. All with just a single dose.
Schatzman added that when data was release last June, investors were focused on the drug's primary endpoint, where it came in at the low end of expectations. The thinking was that Eptinezumab might not be competitive. But after this round of tests, it's clear the drug is approvable and will likely be approved next year.
Schatzman said while its true that their drug is an injection or infusion and not a pill, patients with chronic migraines need relief and they don't care what form that relief comes in.
Cramer said he has high hopes for Alder BioPharmaceuticals.
Cramer and the AAP team are ringing the register on Nucor (NUE - Get Report) for a gain of about 20%. Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.
Cramer and the AAP Team dive into bank earnings and the outlook for 2018. Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To read a full recap of this episode of "Mad Money," click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
More of What's Trending on TheStreet: